Author

Yi‐Mi Wu

Michigan Center for Translational PathologyORCID 0000-0002-3789-4445Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Abhijit ParoliaiD· 2 shared Arul M. ChinnaiyaniD· 2 shared Dan R. RobinsoniD· 2 shared Ryan James RebernickiD· 2 shared Xuhong CaoiD· 2 shared Abigail J. ToddiD· 1 shared Anbarasu KumaraswamyiD· 1 shared Caleb ChengiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Abhijit ParoliaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer

Ryan James Rebernick, Liat Hammer, Mahnoor Naseer Gondal, Abhijit Parolia, Yi‐Mi Wu, Noshad Hosseini, Matthew J. Schipper, Anbarasu Kumaraswamy, Matthew McFarlane, Xuhong Cao, Phillip Lee Palmbos, Megan E.V. Caram, David Carl Smith, Sarah Elizabeth Yentz, MI-OncoSeq Team, , Marcin Cieslik

This study identifies genomic drivers of progression and therapeutic outcomes in mCRPC and develops a multi-omic classifier to predict patient survival across multiple therapies.

bioRxiv · Jun 20, 2026 · PreprintCancer Biology

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

Jean Ching-Yi Tien, Jie Luo, Yu Chang, Yuping Zhang, Yunhui Cheng, Xiaoju Wang, Jianzhang Yang, Rahul Mannan, Somnath Mahapatra, Palak Shah, Xiao-Ming Wang, Abigail J. Todd, Sanjana Eyunni, Caleb Cheng, Ryan James Rebernick, , Arul M. Chinnaiyan

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

Cell Reports Medicine · Oct 1, 2024Peer-reviewedCancer Biology